Euglycemic diabetic ketoacidosis development in a patient with type 2 diabetes receiving a sodium-glucose cotransporter-2 inhibitor and a carbohydrate-restricted diet

Sodium-glucose cotransporter-2 (SGLT2) inhibitors have become increasingly prescribed because of their proven protective effects on the heart and kidneys, carbohydrate-restricted diets are popular therapeutic approaches for patients with obesity diabetes. A 28-year-old obese woman recently diagnosed diabetes developed euglycemic diabetic ketoacidosis (DKA) while dapagliflozin, an SGLT2 inhibitor, following a diet. She presented nausea, vomiting, epigastric pain. Hospital tests showed blood glucose 172 mg/dL, metabolic acidosis, increased ketone levels, confirming DKA. Treatment involved discontinuing dapagliflozin administering fluids, glucose, insulin. recovered was discharged fourth day. This is considered case DKA induced by triggered highlights importance physicians in symptoms laboratory results DKA, even normal levels taking diets. It also crucial to advise maintain adequate carbohydrate intake.